278 related articles for article (PubMed ID: 28276625)
1. NKG2D ligand RAE1ε induces generation and enhances the inhibitor function of myeloid-derived suppressor cells in mice.
Qian L; Liu Y; Wang S; Gong W; Jia X; Liu L; Ye F; Ding J; Xu Y; Fu Y; Tian F
J Cell Mol Med; 2017 Sep; 21(9):2046-2054. PubMed ID: 28276625
[TBL] [Abstract][Full Text] [Related]
2. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8
Hu J; Bernatchez C; Zhang L; Xia X; Kleinerman ES; Hung MC; Hwu P; Li S
Cancer Immunol Res; 2017 Apr; 5(4):300-311. PubMed ID: 28223282
[TBL] [Abstract][Full Text] [Related]
3. Induction of NKG2D ligand expression on tumor cells by CD8
Hu J; Xia X; Gorlick R; Li S
Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
[TBL] [Abstract][Full Text] [Related]
4. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells Reprogram Myeloid-Derived Suppressor Cells to Induce TNF-α Release via NKG2D-Ligand Interaction after Cryo-Thermal Therapy.
You J; Wang S; Zhu Y; Zhang Z; Wang J; Lou Y; Yao Y; Hao Y; Liu P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791188
[TBL] [Abstract][Full Text] [Related]
6. Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation.
Markiewicz MA; Carayannopoulos LN; Naidenko OV; Matsui K; Burack WR; Wise EL; Fremont DH; Allen PM; Yokoyama WM; Colonna M; Shaw AS
J Immunol; 2005 Sep; 175(5):2825-33. PubMed ID: 16116168
[TBL] [Abstract][Full Text] [Related]
7. CD45
Mao FY; Zhao YL; Lv YP; Teng YS; Kong H; Liu YG; Wu XL; Hao CJ; Chen W; Duan MB; Han B; Ma Q; Wang TT; Peng LS; Zhang JY; Cheng P; Su CY; Fu XL; Zou QM; Guo G; Guo XL; Zhuang Y
Cell Death Dis; 2018 Jul; 9(7):763. PubMed ID: 29988030
[TBL] [Abstract][Full Text] [Related]
8. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
[TBL] [Abstract][Full Text] [Related]
9. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury.
Zhang C; Wang S; Li J; Zhang W; Zheng L; Yang C; Zhu T; Rong R
Cell Death Dis; 2017 Mar; 8(3):e2695. PubMed ID: 28333137
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota regulates NKG2D ligand expression on intestinal epithelial cells.
Hansen CH; Holm TL; Krych Ł; Andresen L; Nielsen DS; Rune I; Hansen AK; Skov S
Eur J Immunol; 2013 Feb; 43(2):447-57. PubMed ID: 23136011
[TBL] [Abstract][Full Text] [Related]
11. NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and Kupffer cells in a novel murine natural killer cell-dependent fulminant hepatitis.
Hou X; Zhou R; Wei H; Sun R; Tian Z
Hepatology; 2009 Mar; 49(3):940-9. PubMed ID: 19177594
[TBL] [Abstract][Full Text] [Related]
12. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.
Nausch N; Galani IE; Schlecker E; Cerwenka A
Blood; 2008 Nov; 112(10):4080-9. PubMed ID: 18753637
[TBL] [Abstract][Full Text] [Related]
13. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
[TBL] [Abstract][Full Text] [Related]
14. CD11b+Gr-1+ myeloid-derived suppressor cells reduce atherosclerotic lesion development in LDLr deficient mice.
Foks AC; Van Puijvelde GH; Wolbert J; Kröner MJ; Frodermann V; Van Der Heijden T; Van Santbrink PJ; Boon L; Bot I; Kuiper J
Cardiovasc Res; 2016 Aug; 111(3):252-61. PubMed ID: 27234908
[TBL] [Abstract][Full Text] [Related]
15. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
16. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
[TBL] [Abstract][Full Text] [Related]
17. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand.
Nakamura K; Nakayama M; Kawano M; Amagai R; Ishii T; Harigae H; Ogasawara K
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9421-6. PubMed ID: 23690625
[TBL] [Abstract][Full Text] [Related]
18. Activating receptor NKG2D targets RAE-1-expressing allogeneic neural precursor cells in a viral model of multiple sclerosis.
Weinger JG; Plaisted WC; Maciejewski SM; Lanier LL; Walsh CM; Lane TE
Stem Cells; 2014 Oct; 32(10):2690-701. PubMed ID: 24898518
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory cytokine-mediated evasion of virus-induced tumors from NK cell control.
Mishra R; Polic B; Welsh RM; Szomolanyi-Tsuda E
J Immunol; 2013 Jul; 191(2):961-70. PubMed ID: 23772039
[TBL] [Abstract][Full Text] [Related]
20. Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1.
Champsaur M; Beilke JN; Ogasawara K; Koszinowski UH; Jonjic S; Lanier LL
J Immunol; 2010 Jul; 185(1):157-65. PubMed ID: 20530257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
